A cell viability assay template that adapts to your lab's compounds.

This cell viability template ships configured for an MTS-based cytotoxicity assay of doxorubicin against HeLa cells in a 96-well plate, with a 10-step protocol covering cell seeding through 4-parameter logistic curve fit and EC50 reporting. The protocol assumes Promega CellTiter 96 AQueous One Solution (MTS + phenazine ethosulfate), 5,000 cells per well seeded 24 hours prior to treatment, a 9-point doxorubicin serial dilution from 10 µM to 1.5 nM (3-fold steps), 24-hour treatment, 4-hour MTS development, and absorbance read at 490 nm.

Structured fields capture cell, compound, plate, and assay metadata in typed inputs (cell line, seed density, compound, dose range, replicate count, treatment duration, MTS incubation time, A490 readings, blank-subtracted viability, Z'-factor, EC50), so dose-response parameters and well-by-well absorbance are queryable across plates instead of buried in free text. CellTiter reagent, doxorubicin stock, and DMSO controls link to the ELabELN inventory so lot numbers and aliquot tracking flow into every assay record without manual entry. The spreadsheet editor captures the full 8×12 well plate (dose, well, A490, viability) with calculated curve fit parameters in a single structured grid.

The template is intended as a tested baseline for academic, biotechnology, and pharmacology research labs running cytotoxicity screens, drug-dose response profiling, IC50 / EC50 determination, or basic viability QC across cell lines. Configure the cell line, swap the compound, change the dose range and replicate count, or move from MTS to AlamarBlue, CellTiter-Glo, or trypan blue exclusion by editing the readout section. ELabELN's tamper-evident audit trail captures every plate layout, every absorbance reading, and every curve-fit calculation, so the resulting record supports cross-plate reproducibility documentation, lead-compound advancement decisions, and FDA 21 CFR Part 11 review when the lab's quality system requires it.